Mild To Moderate Psoriasis

Using a practical and problem-focused approach, this updated, full-color Third Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis.Written by an international team of key opinion leaders, this resource explores new developments in treatments for the condition and provides clinicians with up-to-date strategies for optimal patient management.

Edited by an expert editorial team from leading dermatology centers, this set consists of two books: Mild to Moderate Psoriasis, Third Edition and Moderate to Severe Psoriasis, Fourth Edition. Using a practical and problem-focused approach, these updated texts equip dermatologists, family practitioners, and internists with a state-of-the-art guide to the clinical management of all forms of psoriasis. The set provides up-to-date treatment strategies for optimum patient management.

Using a practical and problem-focused approach, this updated, full-color Second Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis. Written by an international team of key opinion leaders, this resource explores new treatments for the condition and provides clinicians with up-to-date management strategies for optimum patient management. New to the Second Edition: updates on topical corticosteroids, calcipotriene, tazarotene, tars, anthralin, salicylic acid, and phototherapy new treatments such as tazarotene gel, scalp psoriasis treatment, topical vitamin D, and analogs chapters devoted to lasers and adhesive patches expanded coverage on scalp psoriasis

Using a practical and problem-focused approach, this updated, full-color Third Edition of Mild-to-Moderate Psoriasis equips dermatologists, internists, family practitioners, and residents with a state-of-the-art guide to the clinical management of mild-to-moderate psoriasis.Written by an international team of key opinion leaders, this resource explores new developments in treatments for the condition and provides clinicians with up-to-date strategies for optimal patient management.

Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis patient that are perfect for the dermatologist in daily practice. New to this edition are chapters on day treatment programs, new agents, erythrodermic and pustular psoriasis, special populations, and pharmacogenetics.

This WHO Global report on psoriasis brings the public health impact of psoriasis into focus. The report is written to help raise awareness of the range of ways that psoriasis can affect peoples' lives. It intends to empower policy-makers with practical solutions to improve the health care and social inclusion of people living with psoriasis in their populations. The report highlights that much of the suffering caused by this common and complex disease can be avoided. Improving access to early diagnosis and appropriate treatment for psoriasis requires universally accessible health-care systems that provide people-centered care for patients with complex, lifelong conditions. Governments also have a key role to play in seeking to address the unnecessary social consequences of psoriasis by the challenging the myths and behaviors that lead to the exclusion of patients from healthcare settings and daily life.

Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.

Advances in itch research have elucidated differences between itch and pain but have also blurred the distinction between them. There is a long debate about how somatic sensations including touch, pain, itch, and temperature sensitivity are encoded by the nervous system. Research suggests that each sensory modality is processed along a fixed, direct-line communication system from the skin to the brain. Itch: Mechanisms and Treatment presents a timely update on all aspects of itch research and the clinical treatment of itch that accompanies many dermatological conditions including psoriasis, neuropathic itch, cutaneous t-cells lymphomas, and systemic diseases such as kidney and liver disease and cancer. Composed of contributions from distinguished researchers around the world, the book explores topics such as: Neuropathic itch Peripheral neuronal mechanism of itch The role of PAR-2 in neuroimmune communication and itch Mrgprs as itch receptors The role of interleukin-31 and oncostatin M in itch and neuroimmune communication Spinal coding of itch and pain Spinal microcircuits and the regulation of itch Examining new findings on cellular and molecular mechanisms, the book is a compendium of the most current research on itch, its prevalence in society, and the problems associated with treatment.

This book explores comorbidity in patients with rheumatic diseases and details both care and treatment options in standard clinical practice. Patients with rheumatic diseases are clinically complex, and the interplay of their disease activity with associated conditions may lead to increased morbidity and mortality. Recently there have been major advances in the management of rheumatic diseases, however, without addressing the potential comorbid conditions, including cardiovascular disease; pulmonary disease; and depression; outcomes remain poor. ​​​ With its 19 chapters, covering the management of major rheumatic diseases (e.g. rheumatoid arthritis, systemic lupus erythematosus , and osteoarthritis), potential comorbidities and treatment recommendations, as well as possible interactions between conditions; this book addresses the gap between textbook medicine and day to day patients' care. Authors also discuss the new hot issue of the comorbidity index, comparing the standard tools to the recently developed indices and how they can assist the rheumatologists in determining disease burden, prognosis, and comorbidity probability. This book is an ideal clinical guide and reference that enables rheumatologists, internal medicine physicians, and residents to address the full clinical expression of these rheumatic diseases with views towards prevention or early management of comorbid conditions.

Psoriasis is the most prevalent autoimmune disease in the U.S. • ~125 million people worldwide have psoriasis. Commonly misunderstood and interpreted as a “cosmetic problem, psoriasis is a complex and potentially debilitating disease; nearly 60% of people with psoriasis reported their disease to be a large problem in their everyday life. This issue of Dermatologic Clinics devoted exclusively to psoriasis is edited by two leaders of the International Psoriasis Council, Dr Alan Menter and Dr Chris Griffiths. Topics include: Genetics of psoriasis; Immunopathogenesis of psoriasis; Phenotypical expressions of psoriasis; Psoriasis as a systemic disease with multiple comorbidities; Outcomes measures in the assessment of psoriasis in clinical practice and trials; Update on topical therapies for mild to moderate psoriasis; Phototherapy and photochemotherapy (PUVA) for psoriasis; Current and future oral systemic therapies for psoriasis; Current biological therapies for psoriasis; Future biological therapies for psoriasis; Psoriatic arthritis for the dermatologist; Pharmacogenomics and the future of psoriasis therapies. This information that goes to the heart of clinical practice is equally appropriate, beyond dermatologists, for internal medicine clinicians, primary care physicians, bone & joint specialists; hematologists/oncologists, and researchers in genetic targeted therapy development.